Blue Chip Value Fund, Inc. (NYSE:BLU) declared a distribution of $0.0178 per share. This distribution is payable January 14, 2011, to stockholders of record on December 31, 2010 and will have an ex-dividend date of December 29, 2010. The Fund anticipates that the source of the distribution is from net investment income. The Fund cannot make a final determination as to the source of the distribution until year end. If it is determined that a portion of the distribution is from other than net investment income, the Fund will clarify those sources when it issues its final tax figures by January 12, 2011.
Blue Chip Value Fund, Inc. is a closed ended equity mutual fund launched and managed by Denver Investments. The fund invests in the public equity markets of the United States.
American Video Teleconferencing Corp. (OTCPK:AVOT)
American Video Teleconferencing Corp. has signed an option agreement to acquire two claim blocks in townships of Mekinac and Lajuene, Province of Quebec. These claim blocks are approximately 3600 acres in total and are located 120 miles east of Montreal P.Q. and 50 miles north of Three Rivers P.Q. They are accessible year round with infrastructure in the immediate vicinity. The claims adjoin a property that had one of the highest readings of Rare Earths in North America. Sampling in the 1950s gave readings of 48% combined Cerium, Lanthanum, Neoymium and Yttrium. That property has remained dormant for over 50 years but the new owners plan an extensive exploration program this fall. AVOT, after a lengthy search and after careful due diligence, believes this is going to be one of the most active areas for Rare Earths exploration and our holdings are in the same geological setting as the 48% Rare Earths showing. Rare Earths are in huge demand especially in the United States as China is closing off its exports of these strategic metals to less than 5% of its production. AVOT will aggressively continue to search world wide for opportunities in Precious, Base and Rare Earths metal projects.
China has started to severely restrict the exports of rare-earth materials, which often find use in “green” technology designs, including hybrid vehicles and energy-efficient lighting, as well as in the medical, defense, and consumer markets. The country delivers nearly 100% of the world’s rare-earth materials: 17 metals that are somewhat hard to refine and that tend to occur in the same ore deposits. The cutbacks have resulted in shock waves through the electronics industry and could force design changes in the near future.
Constraints on Chinese exports are creating opportunities for non-Chinese projects.
Enzo Biochem, Inc. (NYSE:ENZ)
Inflammatory Bowel Disease
Inflammatory Bowel Disease (NYSEARCA:IBD) refers to conditions such as ulcerative colitis and Crohn's disease that are characterized by chronic inflammation of the intestine. Although the cause of IBD remains unknown, various features of the disease strongly suggest that autoimmunity is a major component of the pathogenesis. This suggests that Enzo's immune regulation technology platform may offer an effective treatment for IBD
IBD patients are currently managed during short-term episodes through the use of anti-inflammatory medications, or immunosuppressants such as corticosteroids. These provide symptomatic relief over short periods of time, but do not deliver a cure. These non-specific drugs all act by a generalized suppression of the immune response, with the unfortunate side effect of increasing the patient's susceptibility to infection. ENZ's drug candidate, AlequelT, is designed as a therapeutic modality that specifically quiets the inflammatory responses associated with IBD but does not induce a generalized immune suppression.
Approximately one million people in the United States suffer from IBD. In recent years the total treatment market exceeded 1.5 billion dollars.
Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. ENZ operates in three segments: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. The Enzo Life Sciences segment manufactures, develops, and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers. It offers products applied in the fields of antibiotics, autophagy, cancer, cell cycle, cell death, cell signaling, cell trafficking, genomics/molecular biology, immunology, inflammation, lipid signaling, neurobiology, protein degradation, ROS/RNS, and stress/heat shock. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 30 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The Enzo Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene regulation for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. ENZ sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, Belgium, and Germany. ENZ was founded in 1976 and is headquartered in New York, New York.
To learn more about ENZ visit: http://www.enzo.com
Vaalco Energy Inc. (NYSE:EGY) announced to provided an update on its horizontal development well (ET-7H) in a known separate fault block in the Etame field and on its exploration well (ETOMG-1) on the Omangou prospect, both wells located offshore Gabon. The Company has laid and connected production, service and gas lift lines between the sub-sea tree and the Company's floating production, storage and offloading ("FPSO") facilities.
VAALCO Energy, Inc., an independent energy company, engages in the acquisition, exploration, development, and production of crude oil and natural gas.******
American DG Energy, Inc. (AMEX:ADGE) announced that it has entered into definitive agreements to sell an aggregate of 500,000 shares of its common stock and warrants to purchase an aggregate of 500,000 shares of the Company's common stock in a registered direct offering expected to result in net proceeds of approximately $1 million after deducting placement agency fees and estimated offering expenses. The warrants will be exercisable at an exercise price of $3.25 per share beginning six months after the date of issuance and will expire five years after they first become exercisable.
American DG Energy Inc. distributes, owns, and operates on-site energy systems that produce electricity, hot water, heat, and cooling. It offers natural gas powered cogeneration systems, which produce electricity from an internal combustion engine.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received from the company 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (OTCPK:AVOT) for 12 months IR Services and 1,000,000 shares of (144) restricted common stock for its IT services.